statements

Evonile Pharma Ltd.

BSE: 500672

Sector: Healthcare

Industry Group: Pharmaceuticals & Biotechnology

Industry: Pharmaceuticals

1,824.50+137.8 (+8.17%)

23 Oct, 12:00 AM

Overview Analysis Statements

Technicals Forecast Peers Resources News

Income Statement

Abridged

Understanding Income Statement

Evonile Pharma Ltd. income statement covering revenue, operating profit, EBITDA, PAT and EPS across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	C 2012 Mar 31	2013 Mar 31	R 2014 Mar 31	R 2015 Mar 31	R 2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31	TTM Jun 30
	C 2012 Mar 31	2013 Mar 31	R 2014 Mar 31	R 2015 Mar 31	R 2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31	TTM Jun 30
Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M IR
Total Revenue	844.29	903.36	862.23	873.38	689.77	656.22	563.88	490.68	438.25	381.35	399.87	378.74	335.07	356.27	354.33	370.59
Cost of Operating Revenue	314.15	375.24	407.25	367.40	294.97	315.03	252.29	205.29	198.50	161.79	191.12	210.68	204.99	207.91	202.82	209.11
Gross Profit	530.14	528.12	454.98	505.98	394.80	341.19	311.59	285.39	239.75	219.56	208.75	168.06	130.08	148.36	151.51	161.48
Gross Margin	62.8	58.5	52.8	57.9	57.2	52.0	55.3	58.2	54.7	57.6	52.2	44.4	38.8	41.6	42.8	43.6
Total Operating Expenses	700.69	816.04	885.06	882.46	658.54	633.92	572.31	478.03	437.41	366.58	382.27	318.66	272.15	266.20	259.50	270.66
Operating Profit	143.60	87.32	-22.83	-9.08	31.23	22.30	-8.43	12.65	0.84	14.77	17.60	60.08	62.92	90.07	94.83	99.93
Operating Margin	17.0	9.7	-2.6	-1.0	4.5	3.4	-1.5	2.6	0.2	3.9	4.4	15.9	18.8	25.3	26.8	27.0
Financing Income/(Expense) - Net	70.79	73.62	78.79	92.21	71.59	62.53	140.90	40.77	27.36	16.35	16.13	51.55	53.43	39.82	34.70	-1.22
Profit before Taxes	224.69	169.42	69.86	91.86	111.37	91.73	157.52	85.77	28.64	40.04	-3.82	115.38	122.84	130.42	129.66	135.61
Income Taxes	72.67	49.69	-15.88	12.53	38.88	34.51	79.16	34.00	12.57	19.14	-0.10	12.02	37.65	29.52	36.48	37.84
Profit after Tax	152.02	119.73	98.53	79.11	198.29	57.22	78.36	51.77	10.08	20.90	-3.72	103.36	85.19	100.90	93.18	97.77
PAT Margin	18.0	13.3	11.4	9.1	28.7	8.7	13.9	10.6	2.3	5.5	-0.9	27.3	25.4	28.3	26.3	26.4
EPS - Basic - ex Extraordinary Items	47.56	37.46	26.83	24.82	22.68	19.10	28.43	20.97	6.51	8.46	-1.51	41.86	34.50	40.87	37.74	39.61
EPS - Diluted - ex Extraordinary Items	47.56	37.46	26.83	24.82	22.68	19.10	28.43	20.97	6.51	8.46	-1.51	41.86	34.50	40.87	37.74	39.61
EBIT	143.60	87.32	-22.83	-9.08	31.23	22.30	-8.43	12.65	0.84	14.77	17.60	60.08	62.92	90.07	94.83	99.93
EBITDA	146.32	90.95	-19.16	-5.07	34.72	25.89	-5.90	15.83	13.98	26.93	27.25	66.14	65.53	92.26	96.78	101.77
EBITDA Margin	17.3	10.1	-2.2	-0.6	5.0	3.9	-1.0	3.2	3.2	7.1	6.8	17.5	19.6	25.9	27.3	27.5

Balance Sheet

Abridged

Understanding Balance Sheet

Evonile Pharma Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	C 2012 Mar 31	2013 Mar 31	R 2014 Mar 31	R 2015 Mar 31	R 2016 Mar 31	C 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	C 2012 Mar 31	2013 Mar 31	R 2014 Mar 31	R 2015 Mar 31	R 2016 Mar 31	C 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Source:	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR
Total Current Assets	933	1,034	1,061	1,064	1,264	973	952	805	812	723	708	677	699	746	768
Long-Term Investments	2	0	0	0	0	0	0	1	1	1	1	1	0	0	0
Property Plant & Equipment - Net	10	10	8	8	7	6	5	15	76	64	24	19	7	5	3
Total Non-Current Assets	101	108	141	175	169	177	158	177	266	279	250	306	226	202	210
Total Assets	1,034	1,141	1,202	1,239	1,433	1,150	1,111	982	1,078	1,002	958	983	925	948	978
Total Current Liabilities	193	212	212	177	204	186	331	185	233	159	216	159	157	142	145
Long Term Debt	0	-	-	-	-	-	-	-	56	50	18	17	5	3	2
Total Non-Current Liabilities	23	29	29	29	34	44	46	38	124	132	49	48	23	21	15
Total Liabilities	216	241	241	206	239	230	377	223	357	291	266	207	180	163	160
Total Shareholders' Equity	818	900	961	1,033	1,194	920	734	759	721	711	692	776	745	785	818
Total Equity	818	900	961	1,033	1,194	920	734	759	721	711	692	776	745	785	818
Total Liabilities & Equity	1,034	1,141	1,202	1,239	1,433	1,150	1,111	982	1,078	1,002	958	983	925	948	978

Cash Flow

Abridged

Understanding Cash Flow Statement

Evonile Pharma Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	R 2012 Mar 31	2013 Mar 31	C 2014 Mar 31	2015 Mar 31	C 2016 Mar 31	C 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	R 2012 Mar 31	2013 Mar 31	C 2014 Mar 31	2015 Mar 31	C 2016 Mar 31	C 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR
Operating CF bef Changes in Working Cap	140	115	62	57	-121	64	94	8	11	14	-13	89	139	117	99
Working Capital - Increase/(Decrease)	5	-30	11	-32	80	-38	121	-158	-2	-69	67	-24	9	-1	-14
Net CF from Operating Activities	145	85	73	25	-41	26	214	-150	9	-55	54	65	148	116	85
Capital Expenditures - Net	4	4	1	5	2	3	-16	-16	1	-5	1	-4	-3	0	0
Net CF from Investing Activities	-113	-93	-56	634	-693	356	15	230	17	74	72	-173	-2	-45	-20
Dividends Paid - Cash - Total	32	32	32	32	32	32	28	25	25	25	25	25	117	62	62
Stock - Issuance/(Retirement) - Net	-	-	-	-	-	-293	-234	-	-	-	-	-	-	-	-
Debt - LT & ST - Issuance/(Retirement) - Total	0	0	0	0	-	-	-	-	-5	-6	-11	-6	-4	-2	-2
Net Cash Flow from Financing Activities	-37	-37	-38	-37	-38	-331	-268	-30	-35	-30	-36	-30	-121	-64	-64
Free Cash Flow to Equity	141	81	72	20	-44	23	231	-134	3	-56	43	63	148	114	82
Free Operating CF net dividend	109	49	40	-12	-75	-9	186	-189	-17	-80	29	40	-	-	23
Free Operating CF	141	81	72	20	-44	23	214	-164	8	-55	54	64	-	-	84

Business Segment Analysis

FY End:

Mar 26

Evonile Pharma Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Pharamaceutical Business (100.0%)₹ 0.34 Cr

Revenue / Sales

Pharamaceutical Business (100.0%)₹ 354.33 Cr

Assets

Pharamaceutical Business (100.0%)₹ 978.27 Cr

Operating Income

Pharamaceutical Business (100.0%)₹ 94.83 Cr

Regional Segment Analysis

FY End:

Mar 17

Evonile Pharma Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

India (98.8%)₹ 648.40 CrOther Countries. (1.2%)₹ 7.83 Cr

Historical Segment Analysis

Track how Evonile Pharma Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2010 Mar 31	2011 Mar 31	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	2017 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2026 Mar 31
	2010 Mar 31	2011 Mar 31	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	2017 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2026 Mar 31
Pharamaceutical Business	-	-	-	-	-	-	-	-	1	0	1	0	0
Animal Health	0	0	0	0	0	0	0	0	-	-	-	-	-
Generics	0	0	0	0	0	0	-	-	-	-	-	-	-
OTC	0	0	0	0	0	0	-	-	-	-	-	-	-
Pharmaceuticals	2	2	1	1	1	1	1	1	-	-	-	-	-
Unallocated Corporate	0	1	3	3	1	4	1	2	-	-	-	-	-

Frequently Asked Questions

What is the revenue of Evonile Pharma Ltd.?

The latest trailing twelve month revenue of Evonile Pharma Ltd. is ₹ 370.59 Cr, reflecting a 1-year growth of 5.42% and a 3-year CAGR of 2.08%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Evonile Pharma Ltd.?

The latest trailing twelve month net profit (PAT) of Evonile Pharma Ltd. is ₹ 97.77 Cr, with a 3-year earnings CAGR of 11.15%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Evonile Pharma Ltd.?

The trailing twelve month EBITDA of Evonile Pharma Ltd. is approximately ₹ 99.93 Cr (based on an operating margin of 26.97%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Evonile Pharma Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Evonile Pharma Ltd. is 39.61. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Evonile Pharma Ltd.?

The debt-to-equity ratio of Evonile Pharma Ltd. stands at 0.00. The interest coverage ratio is 81.91x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Evonile Pharma Ltd.?

The estimated book value per share of Evonile Pharma Ltd. is 331.23 (derived from a P/B ratio of 5.51 and market price of ₹ 1,824.50), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Evonile Pharma Ltd.?

The trailing twelve month operating cash flow of Evonile Pharma Ltd. is ₹ 84.70 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Evonile Pharma Ltd. report consolidated or standalone financials?

Evonile Pharma Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.